When amyloid chooses sides: septal affection pattern as an atypical presentation of transthyretin amyloid cardiomyopathy.

Int J Cardiovasc ImagingMay 6, 2026 (epub)
Case ReportCardiologyOpen access

Lea A Maurer, Annina A Studer Bruengger, Muriel S Wiedemann Buser et al.

✦ AI-curated · Sources linked

Case in brief

A 73-year-old man with wild-type transthyretin amyloid cardiomyopathy had an atypical pattern of cardiac involvement on multimodality imaging. Technetium-99m DPD scintigraphy showed uptake almost exclusively in the ventricular septum. Cardiovascular magnetic resonance likewise demonstrated predominantly septal diffuse late gadolinium enhancement and elevated extracellular volume, while echocardiographic strain showed markedly impaired longitudinal strain in septal LV segments. The findings illustrate that ATTR-CM can have a markedly asymmetric distribution rather than the classically described pattern of more symmetrical basal and midventricular involvement.

What made this case unusual

Amyloid involvement was concentrated almost exclusively in the ventricular septum across scintigraphy, CMR, and echocardiographic strain—an atypical distribution for ATTR-CM.

Diagnostic / clinical pearl

A septum-predominant pattern on cardiac imaging does not exclude ATTR-CM; interpret scintigraphy, CMR, and strain findings together.

Source

Published in Int J Cardiovasc Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.